Cardlytics Inc. (NASDAQ:CDLX)’s traded shares stood at 0.46 million during the last session, with the company’s beta value hitting 2.47. At the close of trading, the stock’s price was $27.67, to imply an increase of 3.94% or $1.05 in intraday trading. The CDLX share’s 52-week high remains $134.91, putting it -387.57% down since that peak but still an impressive 9.18% since price per share fell to its 52-week low of $25.13. The company has a valuation of $944.38M, with average of 483.88K shares over the past 3 months.
Analysts have given a consensus recommendation of an Overweight for Cardlytics Inc. (CDLX), translating to a mean rating of 2.50. Of 6 analyst(s) looking at the stock, 0 analyst(s) give CDLX a Sell rating. 0 of those analysts rate the stock as Overweight while 3 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$0.43.
Cardlytics Inc. (NASDAQ:CDLX) trade information
After registering a 3.94% upside in the last session, Cardlytics Inc. (CDLX) has traded red over the past five days. The stock hit a weekly high of 29.82 this Friday, 05/27/22, jumping 3.94% in its intraday price action. The 5-day price performance for the stock is -6.17%, and -22.01% over 30 days. With these gigs, the year-to-date price performance is -58.13%.
Analysts on Wall Street suggest a consensus price target of $57.00, implying an increase of 51.46% to the stock’s current value. The extremes give us $47.00 and $72.00 for target low and target high price respectively. As such, CDLX has been trading -160.21% off suggested target high and -69.86% from its likely low.
Cardlytics Inc. (CDLX) estimates and forecasts
Looking at statistics comparing Cardlytics Inc. share performance against respective industry, we note that the company has underperformed competitors. Cardlytics Inc. (CDLX) shares are -60.92% down over the last 6 months, with its year-to-date growth rate lower than industry average at -30.00% against 15.90%. Revenue is forecast to shrink -10.30% this quarter before falling -18.20% for the next one. The rating firms project that company’s revenue will grow 31.80% compared to the previous financial year.
Revenue forecast for the current quarter as set by 6 analysts is $77.53 million. Meanwhile, for the quarter ending Sep 2022, a total of 6 analyst(s) estimate revenue growth to $87.61 million.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -0.30% for the past 5-year period. While 2022 is set for a -96.00% return in earnings, projections for the next 5 years are at -1.00% annually.
Cardlytics Inc. has its next earnings report out between May 02 and May 06. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Cardlytics Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Cardlytics Inc. (NASDAQ:CDLX)’s Major holders
Cardlytics Inc. insiders hold 2.76% of total outstanding shares, with institutional holders owning 99.44% of the shares at 102.26% float percentage. In total, 99.44% institutions holds shares in the company, led by CAS Investment Partners, LLC. As of Dec 30, 2021, the company held over 5.19 million shares (or 15.20% of shares), all amounting to roughly $342.77 million.
The next major institution holding the largest number of shares is Wellington Management Group, LLP with 3.85 million shares, or about 11.28% of shares outstanding. As of the market price on Dec 30, 2021, these shares were worth $254.32 million.
We also have Vanguard Total Stock Market Index Fund and Vanguard Small-Cap Index Fund as the top two Mutual Funds with the largest holdings of the Cardlytics Inc. (CDLX) shares. Going by data provided on Dec 30, 2021, Vanguard Total Stock Market Index Fund holds roughly 0.85 million shares. This is just over 2.48% of the total shares, with a market valuation of $55.97 million. Data from the same date shows that the other fund manager holds a little less at 0.75 million, or 2.21% of the shares, all valued at about 49.72 million.